{"schema_version":"secwatch.filing_event.v1","accession":"0000950103-26-015465","form_type":"8-K","ticker":"ADCT","cik":"0001771910","company_name":"ADC Therapeutics SA","filed_at":"2026-10-13T10:26:29+00:00","discovered_at":"2026-10-13T10:30:00.271520+00:00","generated_at":"2026-10-13T10:30:31.152890+00:00","sec_items":["1.01","2.02","3.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"ADC Therapeutics announces $86.6M PIPE, Blue Owl loan amendment, HCR royalty amendment, and preliminary Q3 revenue","bullets":["ADC Therapeutics agreed to sell 12,911,347 common shares at $1.4200 and pre-funded warrants for 48,088,653 shares at $1.32400 in an $86.6M private placement expected to close Oct. 22, 2026.","Blue Owl loan amendment prepays $70.0M principal, cuts outstanding term loans to $50.0M, eliminates the minimum liquidity covenant, and sets minimum trailing U.S. ZYNLONTA sales at $65.0M.","HCR Amendment eliminates the $150M change-of-control payment, allows royalty buyout for $525M by Dec. 31, 2029 or $750M after, and cuts permitted third-party debt to $50.0M.","HCR warrants for 9,834,776 shares cut from $3.8130 to $0.10; Lender Warrants for 527,295 shares cut from $8.30 to $1.00.","Preliminary Q3 ZYNLONTA net product revenues ~$21.0M; cash and equivalents $189.2M at Sept. 30, 2026; pro forma ~$196M after $76.3M PIPE net proceeds and $69.6M prepayment."],"urls":{"canonical":"https://secwatch.observer/filing/0000950103-26-015465","json":"https://secwatch.observer/filing/0000950103-26-015465.json","markdown":"https://secwatch.observer/filing/0000950103-26-015465.md","text":"https://secwatch.observer/filing/0000950103-26-015465.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326015465/0000950103-26-015465-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326015465/dp254756_8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-13T10:30:31.152890+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}